紫杉醇联合奥沙利铂与紫杉醇联合奥沙利铂及卡培他滨治疗晚期转移性鼻咽癌的临床研究  

The Study of Paclitaxel,Oxaliplatin and Capecitabine in the Treatment of Metastatic Nasopharyngeal Carcinoma

作　　者：伏瑞祥 林大任[2] 李明毅[2] 谭洁媚[2] 何景扬[2] 

机构地区：[1]江苏泰州中国医药城医院肿瘤科,江苏泰州225300 [2]广东省江门市中心医院肿瘤科,广东江门529000

出　　处：《中国医药指南》2012年第26期33-34,共2页Guide of China Medicine

摘　　要：目的研究紫杉醇联合奥沙利铂及卡培他滨治疗晚期转移性鼻咽癌的疗效及毒副反应。方法 95例晚期转移性鼻咽癌患者分为两组,试验组55例：PTX 135mg/m2d1,L-OHP 130mg/m2d1,CAPE 1650mg/m2d1~14;对照组40例：PTX 135mg/m2 d1,L-OHP 130mg/m2d1;3周为一个周期,化疗结束2~3周后评价疗效。结果 95例患者可评价疗效：试验组有效率50.9%,中位生存时间10.6个月,对照组有效率52.5%,中位生存时间12.1个月,两组有效率及中位生存期差异不显著（P〉0.05）。试验组患者Ⅲ～Ⅳ度手足综合症及消化道毒副反应发生率明显高于对照组（P〈0.05）。结论对于晚期转移性鼻咽癌,紫杉醇、奥沙利铂、卡培他滨三药组合耐受性差,未见生存优势。Objective To study the efficacy and adverse effect of paclitaxel/oxaliplatin plus capecitabine for patients with metastatic nasopharyngeal carcinoma.Methods 95patients with metastatic nasopharyngeal carcinoma were divided into two groups.Fifty five patients received three kind of drugs： paclitaxel 135mg/m2 d1,oxaliplatin 130mg/ m2 d1,and capecitabine 1650mg/m2 d1～14;the others were given paclitaxel 135mg/m2 d1 and oxaliplatin 130mg/ m2 d1.The two regimes were repeated every three weeks.The evaluation was performed two to three weeks after the completion of chemotherapy.Results Ninty five patients could be evaluated.The curative rates of the two groups were 50.9% and 52.5%%（P0.05）,and the median survival were 10.6 months and 12.1 months（P0.05）.For the adverse effect of chemotherapy,the rates of grade Ⅲ～Ⅳ hand-foot syndrome and gastrointestinal discomfortment of the treatment group were higher（P0.05）.Conclusion For the patients of metastatic nasopharyngeal carcinoma,the regime of paclitaxel/oxaliplatin plus capecitabine could not be well tolerated,and no optimal efficacy was found.

关 键 词：转移性鼻咽癌 紫杉醇 卡培他滨 奥沙利铂 

分 类 号：R739.63[医药卫生—肿瘤]